vTv Therapeutics (VTVT)
(Delayed Data from NSDQ)
$22.00 USD
-1.33 (-5.70%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $22.34 +0.34 (1.55%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
VTVT 22.00 -1.33(-5.70%)
Will VTVT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for VTVT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VTVT
VTv Therapeutics (VTVT) Reports Q3 Loss, Lags Revenue Estimates
Exact Sciences (EXAS) Reports Q3 Loss, Tops Revenue Estimates
VTVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA
Other News for VTVT
Goldman Sachs raises obesity drug market estimate to $130B
CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
Cantex Pharmaceuticals receives FDA Orphan Drug Designation for its pancreatic cancer treatment
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF PANCREATIC CANCER
VTv Therapeutics: Q1 Earnings Snapshot